Side-by-side · Research reference
GlutathionevsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED6/39 cited
BFDA-ApprovedFlagship14/45 cited
Glutathione
Endogenous Tripeptide · Antioxidant
IV · Oral · Inhaled
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
Glutathione
Liraglutide
Primary target
Intracellular redox systems, glutathione peroxidase, glutathione transferase
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025Hecht 2026
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Antibody development
—
—
02Dosage Protocols
Parameter
Glutathione
Liraglutide
Endogenous synthesis
Hepatic synthesis ~10 g/day (basal rate)
Tissue-specific; demand-driven upregulation via Nrf2 signaling.
—
Exogenous oral
250–1000 mg/day
Bioavailability limited; gastric hydrolysis reduces systemic uptake.
—
IV supplementation
600–1200 mg (research protocols)
Used in clinical oxidative stress and hepatic detoxification studies.
—
Precursor strategy
N-acetylcysteine (NAC) 600–1200 mg/day
Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.
—
Evidence basis
Animal mechanistic + human mechanistic
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Frequency
—
Once daily, same time each day
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
Duration
—
Indefinite for chronic indication
Reconstitution
—
Pre-filled commercial pen (no reconstitution)
Timing
—
Any time of day; consistent
04Side Effects & Safety
Parameter
Glutathione
Liraglutide
Oral supplementation
GI discomfort, bloating (mild, dose-dependent)
—
IV administration
Rare hypersensitivity, infusion site reaction
—
Inhalation
Bronchospasm risk in asthma (rare)
—
Tumor metabolism
Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026
—
GI symptoms
—
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Pregnancy / OB
—
Contraindicated
Absolute Contraindications
Glutathione
—Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
Glutathione
- ·Active malignancy (theoretical cysteine supply risk)Hecht 2026
- ·Severe asthma (inhaled formulations)
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
Glutathione
Liraglutide
1. Oral administration
Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.
Commercial pre-filled pen, no reconstitution required.
2. Intravenous
Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Inhaled formulations
Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.
Once daily, same time each day. Take with or without food.
4. Precursor supplementation
N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Needle
—
Pen-supplied 32G needle.